Summary
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
CytoDyn Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| VWA VSM Wealth Advisory LLC VSM Wealth Advisory LLC | 500 | $137 | $108.4 | -$28.6 | -20.88% |
CytoDyn Inc. (CYDY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CytoDyn Inc. ever had a stock split?
CytoDyn Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jacob Lalezari CEO | OTCQB Exchange | 23283M101 CUSIP |
| US Country | 13 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CytoDyn Inc. is a clinical-stage biotechnology firm focusing on the development of treatments across multiple therapeutic indications. Originally known as RexRay Corporation, the company was rebranded to CytoDyn Inc. following its incorporation in 2002. Based in Vancouver, Washington, CytoDyn positions itself at the forefront of addressing critical health challenges, including COVID-19, HIV, metabolic dysfunction-associated steatohepatitis (MASH), and various forms of cancer, specifically targeting metastatic triple-negative breast cancer. Through dedicated research and development, CytoDyn aims to leverage cutting-edge biotechnological approaches to improve health outcomes for patients worldwide.
Products and Services
CytoDyn is involved in the clinical development of its flagship therapeutic candidate, leronlimab:
- Leronlimab (COVID-19): This novel humanized monoclonal antibody is aimed at combating the novel coronavirus by targeting the C-C chemokine receptor type 5 (CCR5). Its potential in COVID-19 treatment highlights CytoDyn's commitment to addressing global health emergencies.
- Leronlimab (HIV): Designed to target the CCR5 receptor, leronlimab is under development as a promising therapeutic option for patients suffering from human immunodeficiency virus (HIV) with the potential to improve patient outcomes significantly.
- Leronlimab (Metabolic Dysfunction-Associated Steatohepatitis - MASH): In the realm of metabolic disorders, leronlimab is in phase 2 development for treating NASH, a serious liver disease, showcasing CytoDyn's expansion into treatments for metabolic dysfunction.
- Leronlimab (Solid Tumors in Oncology): The company is exploring the efficacy of leronlimab in treating solid tumors, including metastatic triple-negative breast cancer. This involves investigating the antibody's impact on tumor growth and metastasis in the oncology sector.
- Leronlimab (HIV NASH): Beyond standard HIV treatment, leronlimab is being studied for its effectiveness in patients suffering from both HIV and NASH, exemplifying a multifaceted approach to complex co-morbidities.
- Leronlimab (HIV-PreP and HIV-Cure): CytoDyn is also advancing pre-clinical developments with leronlimab for both the prevention (PrEP) and the cure of HIV, underpinning a long-term vision toward eradicating the disease.
